A medical, social and economic study of patients with FOP in France

A cross-analysis of the National Rare Diseases Database (BNDMR) and the National Health Data System (SNDS) shows that progressive ossifying fibrodysplasia (FOP):

  • has an estimated prevalence of 1.39 per million inhabitants, affecting 94 patients being treated at specialist centres in France at the end of 2020,
  • shows perfect parity,
  • increases the risk of various comorbidities (malnutrition, depression, urinary stones, respiratory failure), compared with a control group of 769 people without FOP but potentially suffering from one or more other conditions (data from the SNDS),
  • is associated with a mean age at death of 50.4 years, compared with 63.1 years for the control patients, although the difference is not statistically significant,
  • results in total annual healthcare expenditure – including both reimbursed costs and out-of-pocket expenses – that is, on average, more than 10 times higher than that of the control group.

This study also reveals a trend towards increasingly early diagnosis of FOP, which offers hope that the consequences (including the financial impact) of the disease for patients can be reduced through the earlier implementation of appropriate care.